Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gaming your way to recovery: can a sensor-guided tablet exercise prevent hospital deconditioning?

NCT ID NCT04743401

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether a self-administered, tablet-based exercise game, guided by foot-worn sensors, can help hospitalized COVID-19 patients maintain strength and mobility without in-person contact. The program aims to prevent physical decline (deconditioning) during hospital stays, while reducing infection risk to staff. The study includes Veterans and other hospitalized patients expected to stay at least three days, and measures how feasible and acceptable the program is, along with its effects on daily living activities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tele-exergaming tablet program
What this could lead to
If this approach proves feasible, it could offer a safe, remote way to keep hospitalized patients mobile without exposing staff to infection, potentially reducing hospital-related physical decline.
What could go wrong
This is a small feasibility study, not a test of effectiveness. The game may be hard for some patients to use, and results may not apply beyond this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Jul 2021

Finished

Dec 2023

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants: Men or women Veterans with COVID-19 or PUI or hospitalized patients with duration of admission anticipated to be greater than 72 hours admitted to MEDVAMC. * Length of stay: Anticipated length of stay at least 3 days. * Ambulatory. Self-report of being ambulatory with or without an assistive device in the 2 weeks before admission. Exclusion Criteria: * ICU admission: The investigators will exclude those admitted to ICU at any point in their hospital stay. * Admission of observation only: These patients will be excluded as length of stay is usually anticipated to be less than 3 days * Median life expectancy: Those with imminently terminal (death expected in the next 30 days) will be excluded. * Cognitive impairment: The investigators will exclude those with delirium, dementia, or severe cognitive impairment * Medical condition: The investigators will exclude those who have any medical diagnosis deemed by the primary physician to be a contraindication to ambulation (i.e.: unstable from pulmonary embolus, unstable angina, severe hemodynamic instability etc.) * Foot problem: The investigators will exclude those who have active foot ulcer or infection or major lower extremities amputation. * Vision or hearing problems: The investigators will exclude those with hearing or visual problems that cannot be corrected with medical devices (glasses or hearing aids). Hearing or visual problems can limit their ability to interact with the exergame platform. * lack of capacity to consent, and inability or unwillingness to participate regularly in the exercise program; * unable to communicate in English or Spanish, or unlikely to fully comply with the follow-up protocol (e.g., lack of caregiver support to safely perform exercise tasks at home or complete the questionnaires). Clarifying exclusion criteria * Ongoing treatment: The investigators will NOT exclude those who are participating in standard of care physical therapy program (Receipt of Physical Therapy (PT), Occupational Therapy (OT), Speech Therapy (ST), Mental Health (MH), and Social Work (SW) Services). However, the investigators will document these services and will control for it. However, those who are receiving non- standard of care exercise therapy (e.g. other exercise research study) or receiving active intensive or induction therapy for cancer (e.g. undergoing active initial chemotherapy or radiotherapy). * Others: The investigators will NOT exclude but will document common comorbidities such as pneumonia, heart failure, and chronic obstructive pulmonary disease exacerbations. Pulmonary embolism or acute coronary syndrome maybe included if there is no contraindications like severe hemodynamic instability or active angina.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas, 77030-4211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.